Skip to main content

Table 2 Clinical characteristics of the study cohort (N = 26)

From: Gene co-expression networks are associated with obesity-related traits in kidney transplant recipients

Clinical parameterMean ± Standard deviationRange (min; max)
Weight at Baseline
 WT_BL (lbs)174.80 ± 37.54129.19; 257.90
Weight at 3 Months
 WT_3M (lbs)170.22 ± 38.79123.00; 242.00
Weight at 6 Months
 WT_6M (lbs)179.96 ± 39.91133.00; 259.80
Weight at 12 Months
 WT_12M (lbs)182.69 ± 47.33128.00; 294.62
BMI at Baseline
 BMI_BL (kg/m2)27.41 ± 3.3622.30; 33.62
BMI at 3 Months
 BMI_3M (kg/m2)26.68 ± 3.8220.52; 34.85
BMI at 6 Months
 BMI_6M (kg/m2)28.21 ± 3.7322.30; 34.70
BMI at 12 Months
 BMI_12M (kg/m2)28.58 ± 4.9722.64; 39.95
Weight Change at 3 Months
 WT_CHG_3M (%)−2.71 ± 6.10−13.92; 8.13
Weight Change at 6 Months
 WT_CHG_6M (%)3.01 ± 6.69−12.02; 14.24
Weight Change at 12 Months
 WT_CHG_12M (%)4.11 ± 10.83−17.00; 25.84
Subtotal Body Fat at Baseline
 SubTot_Fat_BL (g- below the head)22,006.51 ± 7037.557505.83; 35,429.71
Percent Body Fat at Baseline
 SubTot_Pfat_BL (%)29.79 ± 7.3914.05; 38.47
Whole Body Fat at Baseline
 WB_Tot_Pfat_BL (g)29.25 ± 6.9514.50; 37.60
Subtotal Body Fat at 12 Months
 SubTot_Fat_12M (g- below the head)26,416.99 ± 9604.7114,528.39; 49,349.50
Percent Body Fat at 12 Months
 SubTot_Pfat_12M (%)34.07 ± 6.8519.20; 50.19
Whole Body Fat at 12 Months
 WB_Tot_Pfat_12M (%)33.28 ± 6.5219.25; 48.84
Creatininie at Baseline
 CREATININE_BL (mg/dL)6.24 ± 3.601.20; 14.10
Glucose at Baseline
 GLUCOSE_BL (mg/dL)116.50 ± 44.2370.00; 234.00
Creatinine at 3 Months
 CREATININE_3M (mg/dL)1.58 ± 0.421.00; 2.50
Glucose at 3 months
 GLUCOSE_3M (mg/dL)125.68 ± 51.4670.00; 266.00
Creatininte at 6 Months
 CREATININE_6M (mg/dL)1.42 ± 0.281.00; 1.90
Glucose at 6 Months
 GLUCOSE_6M (mg/dL)121.48 ± 37.7279.00; 224.00
Creatinine at 12 Months
 CREATININE_12M (mg/dL)1.60 ± 0.450.85; 2.68
Glucose at 12 Months
 GLUCOSE_12M (mg/dL)135.29 ± 59.5078.00; 285.00
Height (in)66.61 ± 4.0760.00; 75.00